Page 5 - க்ளேண்மர்க் மருந்துகள் வரையறுக்கப்பட்டவை ஸ்டாக் பரிமாற்றம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from க்ளேண்மர்க் மருந்துகள் வரையறுக்கப்பட்டவை ஸ்டாக் பரிமாற்றம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In க்ளேண்மர்க் மருந்துகள் வரையறுக்கப்பட்டவை ஸ்டாக் பரிமாற்றம் Today - Breaking & Trending Today

Glenmark launches affordable drug to treat kidney cancer in India


Glenmark launches affordable drug to treat kidney cancer in India
Glenmark launches affordable drug to treat kidney cancer in India
16 February 2021 | News
The drug is launched at a MRP that is approximately 96 per cent lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg) and Rs 1840 (12.5 mg) per month
Source credit: Shutterstock
Glenmark Pharmaceuticals has launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. The drug is launched at a MRP that is approximately 96 per cent lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg) and Rs 1840 (12.5 mg) per month. Sunitinib is also approved by the US Food and Drug Administration (US FDA).  ....

Alok Malik , Group Vice , Drug Administration , Glenmark Pharmaceuticals , Group Vice President , Business Head , India Formulations , Kidney Cancer , Stromal Tumours , Advanced Renal Cell Carcinoma , Pancreatic Neuroendocrine Tumours , அலோக் மாலிக் , குழு துணை , க்ளேண்மர்க் மருந்துகள் , குழு துணை ப்ரெஸிடெஂட் , வணிக தலை , இந்தியா சூத்திரங்கள் , கிட்நீ புற்றுநோய் ,

Board of Glenmark Pharmaceuticals approves buyback of Singapore listed FCCBs


At meeting held on 12 February 2021The Board of Glenmark Pharmaceuticals at its meeting held on 12 February 2021 has approved opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds, being, its U.S.$200 million (as on date outstanding U.S.$ 113.5 million) 2 per cent resettable onward starting equity linked
securities due 28 June 2022 issued in 2016 (FCC Bonds) by the Company (Bond Repurchase ), based on market opportunities and conditions from time to time.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader, ....

Board Of Glenmark Pharmaceuticals , Company Bond , Glenmark Pharmaceuticals , Capital Market , Hurunui District , Anders Glenmark , Singles Bar , Federal Communications Commission , பலகை ஆஃப் க்ளேண்மர்க் மருந்துகள் , நிறுவனம் பத்திரம் , க்ளேண்மர்க் மருந்துகள் , மூலதனம் சந்தை , ஆண்டர்ஸ் க்ளேண்மர்க் , ஒற்றையர் மதுக்கூடம் , கூட்டாட்சியின் தகவல்தொடர்புகள் தரகு ,

Glenmark's consolidated Net Profit rises by 30.05% to Rs. 2481.79 Mn. in Q3 FY 2020-21


Share this article
MUMBAI, Feb. 12, 2021 /PRNewswire/
Glenmark s consolidated sales rises by 3.88% to Rs. 27,605.07 Mn. in Q3 FY 2020-21 
Consolidated EBITDA rises by 20.45% to Rs. 5300.72 Mn. in Q3 FY 2020-21
Highlights for Q3 FY 2020-21
India Business grew by 11.82% to Rs. 8,821.19 Mn.
Europe Business grew by 1.42% to Rs. 3,133.29 Mn.
US Business experienced sales decline of (2.43%) to Rs. 7,803.87 Mn.
API Business grew by 22.09% to 3,200.70 Mn.
Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced its financial results for the third quarter ended December 31 of the financial year 2020-21.
For the third quarter of FY 2020-21, Glenmark s consolidated sales was at Rs. 27,605.07 Mn. as against Rs. 26,574.51 Mn. recording an increase of 3.88 %. ....

Slovak Republic , United States , Czech Republic , Indian Pharma , Glenn Saldanha , Glenmark Europe , Glenmark Life Sciences , Glenmark Pharmaceuticals , Glenmark Pharmaceuticals Inc , Glenmark Pharmaceuticals Ltd , Pharmaceuticals Limited , Net Profit , Managing Director , Third Quarter , Pharmaceuticals Inc , Central Eastern European , Western European , Latin American , Life Sciences , Glenmark Life Sciences Limited , Dow Jones Sustainability Index , Corporate Sustainability , ஸ்லோவாக் குடியரசு , ஒன்றுபட்டது மாநிலங்களில் , செக் குடியரசு , இந்தியன் பார்மா ,

Glenmark Q3 results: Net profit rises by 30% to Rs 248 crore


Glenmark Q3 results: Net profit rises by 30% to Rs 248 crore
The company had posted a net profit of Rs 190.83 crore for the corresponding period of the previous fiscal, Glenmark Pharmaceuticals said in a regulatory filing
PTI | February 13, 2021 | Updated 13:10 IST
Representational Image (Photo-Reuters)
Drug firm Glenmark Pharmaceuticals on Friday reported a 30.04 percent rise in its consolidated net profit to Rs 248.17 crore for the quarter ended December 2020, mainly on account of robust sales in India and growth in the API segment. The company had posted a net profit of Rs 190.83 crore for the corresponding period of the previous fiscal, Glenmark Pharmaceuticals said in a regulatory filing. ....

United States , Glenn Saldanha , Glenmark Europe , Glenmark Pharmaceuticals , Glenmark Pharmaceuticals Inc , Glenmark Pharmaceuticals On , Pharmaceuticals Chairman , Pharmaceuticals Inc , Glenmark Quarterly Results , ஒன்றுபட்டது மாநிலங்களில் , க்ளென் சால்தான் , க்ளேண்மர்க் யூரோப் , க்ளேண்மர்க் மருந்துகள் , க்ளேண்மர்க் மருந்துகள் இன்க் , க்ளேண்மர்க் மருந்துகள் ஆன் , மருந்துகள் தலைவர் , மருந்துகள் இன்க் , க்ளேண்மர்க் காலாண்டு முடிவுகள் ,